Recent 8-K filings for APVO

• May 27, 2026, 4:05 PM ET other material materiality 0.75 positive item 1.01item 3.02item 7.01item 9.01

  Aptevo (APVO) partners with Niowave for radiopharma development; Niowave takes 7.9% equity stake

  50/50 strategic collaboration to develop up to three radiopharmaceutical oncology programs using Aptevo's multispecific platforms and Niowave's radioisotopes.

• May 13, 2026, 4:05 PM ET other material materiality 0.65 positive item 2.02item 9.01

  Aptevo reports 81% remission rate for mipletamig in frontline AML; $60M equity line secured

  Mipletamig plus venetoclax/azacitidine: 87% clinical benefit rate, 81% CR/CRi, 65% CR in 31 evaluable patients; no CRS.

• May 6, 2026, 7:59 PM ET other material materiality 0.90 positive item 8.01item 9.01

  Aptevo Reports 87% Clinical Benefit Rate and 81% Remission in Frontline AML Trial RAINIER

  Across 31 evaluable frontline AML patients, mipletamig combo showed 87% clinical benefit rate and 81% remission (CR/CRi), outperforming VIALE-A benchmark of 66.4%.

• March 26, 2026, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  Aptevo FY2025 net loss $26M, cash $21.6M; mipletamig 86% CBR in AML; CEO transition

  Mipletamig triplet in 28 frontline AML patients: 86% CBR, 79% CR/CRi, no CRS observed.

• March 11, 2026, 7:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  Aptevo reports 86% clinical benefit rate for mipletamig combo in frontline AML, zero CRS

  Mipletamig + venetoclax + azacitidine showed 86% clinical benefit rate (CR/CRi/PR) in 28 evaluable frontline AML patients.

• February 19, 2026, 6:59 PM ET other material materiality 0.15 negative item 5.07

  Aptevo shareholders approve issuance of >19.99% of common stock to Yorkville

  Shareholders approved issuance of more than 19.99% of outstanding common stock under Standby Equity Purchase Agreement with Yorkville.

• February 3, 2026, 6:59 PM ET leadership materiality 0.75 positive item 5.02item 9.01

  Marvin White retires as Aptevo CEO; COO Jeff Lamothe named successor effective April 1, 2026

  White to become Executive Chair; Lamothe promoted from COO to President and CEO and appointed to Board.

• January 9, 2026, 6:59 PM ET other material materiality 0.65 positive item 1.01item 3.02item 8.01item 9.01 ◈ Material Agreements

  Aptevo secures $60M equity line with Yorkville, extends funding runway into 2029

  Enters $60M Standby Equity Purchase Agreement with Yorkville; minimal fees, no warrants.

• December 29, 2025, 6:59 PM ET other materiality 0.60 negative item 5.03item 9.01 ◈ Governance Changes

  Aptevo Therapeutics files 1-for-18 reverse stock split effective Dec 29, 2025

  Reverse split ratio 1-for-18 approved by board Dec 17; effective Dec 29 at 5:01 PM ET.

• December 9, 2025, 6:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  Aptevo reports mipletamig 93% ORR, zero CRS in frontline AML Phase 1b/2 trial at ASH 2025

  100% of patients free of cytokine release syndrome (CRS) across cohorts 1-3.

• November 6, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Aptevo reports 89% remission in frontline AML with mipletamig; Q3 net loss $7.5M

  89% of evaluable frontline AML patients achieved remission (CR+CRi) across two trials of mipletamig; no cytokine release syndrome observed.

• October 30, 2025, 7:59 PM ET other material materiality 0.25 neutral item 1.01item 3.03item 9.01

  Aptevo extends shareholder rights agreement Final Expiration Date to Oct 29, 2026

  Amendment No. 5 to Rights Agreement extends Final Expiration Date from Nov 2025 to Oct 29, 2026.

• September 16, 2025, 7:59 PM ET other material materiality 0.80 positive item 8.01item 9.01

  Aptevo reports 100% remission rate in Cohort 3 of Phase 1b/2 RAINIER trial for mipletamig in AML

  100% remission rate (CR/CRi) in Cohort 3 with mipletamig + venetoclax + azacitidine for newly diagnosed AML unfit for intensive chemo.

• September 4, 2025, 7:59 PM ET other material materiality 0.60 positive item 8.01item 9.01

  Aptevo expands oncology pipeline with two new trispecific candidates APVO452 and APVO451

  Filed provisional patents for APVO452 (PSMA x CD3 x CD40) targeting prostate cancer and APVO451 (Nectin-4 x CD3 x CD40) for multiple solid tumors.

• August 11, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Aptevo Q2 net loss $6.2M; mipletamig 85% remission in AML; pipeline expands with APVO455

  Net loss $6.2M for Q2 2025; cash $9.4M as of June 30, 2025.

• July 24, 2025, 7:59 PM ET other materiality 0.25 neutral item 5.07

  Aptevo shareholders approve reverse stock split and Yorkville equity issuance

  Elected directors Marvin L. White (443,945 for) and John E. Niederhuber (444,661 for) to board.

• July 1, 2025, 7:59 PM ET regulatory materiality 0.55 positive item 8.01

  Aptevo regains Nasdaq compliance with $15.9M equity raise

  Received Nasdaq notice confirming compliance with minimum $2.5M stockholders' equity rule.

• June 30, 2025, 7:59 PM ET other material materiality 0.80 positive item 8.01

  Aptevo raises $15.9M in Q2 equity offerings, believes it regains Nasdaq compliance on stockholders' equity

  Raised approx. $15.9M via four equity transactions: April 4 ($2.1M), April 22 ($2.0M), June 20 ($8.0M), and ATM facility ($3.8M).

• June 23, 2025, 7:59 PM ET other materiality 0.15 neutral item 4.01item 9.01 ◈ Auditor Changes ×2

  Aptevo Therapeutics appoints Baker Tilly as new auditor after Moss Adams merger

  Moss Adams merged with Baker Tilly effective June 3, 2025; Moss Adams resigned and Baker Tilly appointed for FY2025.

• June 20, 2025, 7:59 PM ET other material materiality 0.85 positive item 1.01item 8.01item 9.01

  Aptevo raises $8M, reports 85% remission for mipletamig in AML, adds APVO455

  Gross proceeds of ~$8M from registered direct offering of 2.465M shares/pre-funded warrants and 12.325M common warrants at $3.25/unit.

• June 20, 2025, 7:59 PM ET other material materiality 0.55 neutral item 9.01

  Aptevo files prospectus supplement for ATM offering of up to $8.0M

  Filed prospectus supplement for ATM offering of up to $8,037,381 in common stock via Roth Capital Partners.

• June 17, 2025, 7:59 PM ET other material materiality 0.65 neutral item 1.01item 3.02item 9.01

  Aptevo Therapeutics enters $25M standby equity purchase agreement with Yorkville

  Up to $25M in common stock may be sold to YA II PN over 36 months at 96% of lowest 3-day VWAP.

• May 23, 2025, 7:59 PM ET other material materiality 0.60 negative item 5.03item 9.01

  Aptevo Therapeutics effects 1-for-20 reverse stock split effective May 23, 2025

  Stockholders approved reverse split 1:6 to 1:20 at May 14 special meeting; board chose 1:20 on May 21.

• May 22, 2025, 7:59 PM ET regulatory materiality 0.80 negative item 3.01item 8.01item 9.01

  Aptevo receives Nasdaq delisting notice for equity deficiency; announces 1-for-20 reverse split

  Nasdaq notified Aptevo of non-compliance with $2.5M stockholders' equity rule; deficit of $1.473M as of March 31, 2025.

• May 15, 2025, 7:59 PM ET other material materiality 0.75 positive item 2.02item 9.01

  Aptevo reports 90% remission rate in frontline AML with mipletamig triplet; no CRS

  9 of 10 frontline AML patients achieved remission with mipletamig + venetoclax + azacitidine across two trials.

• April 29, 2025, 7:59 PM ET other material materiality 0.60 neutral item 8.01item 9.01

  Aptevo files prospectus supplement to sell up to $3.17M in common stock via ATM

  ATM offering of up to $3,167,548 in common stock under sales agreement with Roth Capital Partners.

• April 28, 2025, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 2.02item 8.01item 9.01

  Aptevo enters ATM equity facility up to $2.96M; reports preliminary Q1 cash of $2.1M

  Entered ATM sales agreement with Roth Capital to sell up to $2,959,952 in common stock; Roth receives 3.0% commission.

• April 22, 2025, 7:59 PM ET other material materiality 0.50 neutral item 1.01item 8.01item 9.01

  Aptevo raises $2.0M in registered direct offering at $0.862/share

  Sold 2,324,000 shares at $0.862 each, gross proceeds ~$2.0M; net ~$1.8M after fees.

• April 4, 2025, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 3.02item 8.01item 9.01

  Aptevo raises $2.1M in registered direct offering and private placement; existing warrants amended

  Sold 1,764,710 shares of common stock and warrants to purchase up to 3,529,420 shares at $1.19/unit.

• March 20, 2025, 7:59 PM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

  Two additional AML patients achieve remission in Cohort 2 of RAINIER trial; 90% response rate

  Two additional AML patients in Cohort 2 of RAINIER trial achieved remission within 30 days of treatment.

• February 14, 2025, 6:59 PM ET other material materiality 0.70 positive item 2.02item 9.01

  Aptevo reports 100% remission in Cohort 1 of RAINIER AML trial; 59% stable disease rate in ALG.APV-527 trial

  Mipletamig RAINIER Cohort 1: 100% of patients achieved remission within 30 days, including one MRD-negative status.

• February 11, 2025, 6:59 PM ET other material materiality 0.30 neutral item 7.01item 9.01

  Aptevo Therapeutics provides pipeline update via investor presentation

  Presentation highlights clinical candidates mipletamig and ALG.APV-527.

• December 12, 2024, 6:59 PM ET other material materiality 0.70 positive item 8.01item 9.01

  Aptevo: 100% remission in Cohort 1 of mipletamig frontline AML trial; 2 of 3 patients MRD-negative

  100% of patients (3/3) achieved remission within 30 days in Cohort 1 of RAINIER Phase 1b trial.

• December 12, 2024, 6:59 PM ET other material materiality 0.70 neutral item 1.01item 3.02item 9.01

  Aptevo raises up to $6.2M via warrant exercise inducement; issues new warrants at $9.53

  Holders exercise up to 823,544 existing warrants at $7.50/share for ~$6.2M gross proceeds.

• December 4, 2024, 6:59 PM ET other material materiality 0.40 positive item 8.01item 9.01

  Aptevo unveils preclinical bispecific APVO442 for prostate cancer; targets $14B market

  APVO442 is a PSMA x CD3 bispecific antibody designed to treat prostate cancer.

• December 3, 2024, 6:59 PM ET other material materiality 0.50 neutral item 5.03item 9.01

  Aptevo Therapeutics completes 1-for-37 reverse stock split effective December 3, 2024

  Certificate of Amendment filed with Delaware; split effective at 5:01 p.m. ET on December 3, 2024.

• November 26, 2024, 6:59 PM ET other material materiality 0.15 neutral item 8.01item 9.01

  Aptevo's Peter Pavlik to present ADAPTIR platform at Pep Talk; new molecule expected in early 2025

  Peter Pavlik, PhD, will chair a 'Bi and Multispecific Biologics' session at Pep Talk conference in January 2025.

• November 22, 2024, 6:59 PM ET other material materiality 0.30 neutral item 8.01item 9.01

  Aptevo highlights bispecific pipeline; first AML patient shows 90% blast reduction

  First patient in Phase 1b/2 RAINIER trial for mipletamig achieved 90% leukemic blast reduction within 30 days.

• November 20, 2024, 6:59 PM ET other material materiality 0.70 positive item 8.01item 9.01

  Aptevo reports first RAINIER trial patient achieved 90% leukemic blast reduction in 30 days

  First patient in Phase 1b/2 RAINIER trial achieved 90% reduction in leukemic blasts within first 30 days.

• November 7, 2024, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Aptevo Q3 net loss $5.1M; cash $7.8M; initiates RAINIER trial for AML

  Net loss of $5.1M ($0.48 per share) in Q3 2024 vs $6.3M ($22.16) in Q3 2023.

• November 4, 2024, 6:59 PM ET other material materiality 0.40 neutral item 1.01item 3.03item 9.01

  Aptevo Therapeutics extends poison pill expiration to Oct 2025, adjusts purchase price to $70

  Amendment No. 4 extends Rights Agreement Final Expiration Date to October 31, 2025.

• October 25, 2024, 7:59 PM ET other material materiality 0.70 negative item 5.07

  Aptevo shareholders approve reverse stock split (1:5–1:37) and dilutive stock issuance

  Stock issuance and warrant proposal passed (593,301 For, 412,901 Against, 5,355 Abstain).

• September 18, 2024, 7:59 PM ET other material materiality 0.65 neutral item 1.01item 8.01item 9.01

  Aptevo raises $3.0M via registered direct offering of stock and warrants at $0.33/share

  Issued 9,090,910 shares or pre-funded warrants plus warrants for up to 18,181,820 shares at $0.33 per unit.

• September 16, 2024, 7:59 PM ET other material materiality 0.60 positive item 8.01item 9.01

  Aptevo/Alligator Phase 1 ALG.APV-527 trial: 60% stable disease, 11+ month duration in breast cancer

  Phase 1 data presented at ESMO: 9 of 15 evaluable patients (60%) achieved stable disease across solid tumors.

• August 8, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Aptevo posts Q2 net loss $5.9M, cash $8.1M; APVO436 Phase 1b/2 trial to begin

  Net loss of $5.9M ($1.67/sh) vs $7.9M ($53.95/sh) in Q2 2023; R&D spend down 33% to $3.6M.

• August 7, 2024, 7:59 PM ET other material materiality 0.15 neutral item 5.07

  Aptevo shareholders reject charter amendment, approve stock issuance at special meeting

  Proposal 1 (charter amendment) failed: FOR 929,933 / AGAINST 554,853 / ABSTAIN 24,490; required majority of outstanding shares.

• July 1, 2024, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 8.01item 9.01

  Aptevo raises ~$2.75M gross in registered direct offering at $0.515/share

  Offering of 5,339,806 shares (or pre-funded warrants) and 10,679,612 common warrants at $0.515/share; net proceeds ~$2.3M.

• July 1, 2024, 7:59 PM ET regulatory materiality 0.75 negative item 3.01

  Aptevo receives Nasdaq deficiency notice for bid price below $1.00; 180-day cure period until Dec 23, 2024

  Received Nasdaq Staff letter on June 25, 2024, for failure to meet minimum $1.00 bid price requirement.

• June 10, 2024, 7:59 PM ET other materiality 0.15 neutral item 5.07

  Aptevo stockholders elect two directors, ratify Moss Adams as auditor for 2024

  Daniel J. Abdun-Nabi and Grady Grant III elected to board with ~470K votes for each.

• May 8, 2024, 7:59 PM ET earnings materiality 0.55 neutral item 2.02item 9.01 ◈ Earnings Releases

  Aptevo Q1 net loss $6.8M; breast cancer patient stays on ALG.APV-527 >11 months

  Net loss $6.8M ($9.95 per share) vs net income $2.8M ($17.38 per share) in Q1 2023.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.65 · Most common event other_material

21 positive 6 negative 23 neutral

source · APVO on sec.gov